Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis
Matthew C Choy, Dean Seah, David M Faleck, Shailja C Shah, Che-Yung Chao, Yoon-Kyo An, Graham Radford-Smith, Talat Bessissow, Marla C Dubinsky, Alexander C Ford, Leonid Churilov, Neville D Yeomans, Peter P De Cruz
INFLAMMATORY BOWEL DISEASES | OXFORD UNIV PRESS INC | Published : 2019
BACKGROUND: Infliximab is an effective salvage therapy in acute severe ulcerative colitis; however, the optimal dosing strategy is unknown. We performed a systematic review and meta-analysis to examine the impact of infliximab dosage and intensification on colectomy-free survival in acute severe ulcerative colitis. METHODS: Studies reporting outcomes of hospitalized steroid-refractory acute severe ulcerative colitis treated with infliximab salvage were identified. Infliximab use was categorized by dose, dose number, and schedule. The primary outcome was colectomy-free survival at 3 months. Pooled proportions and odds ratios with 95% confidence intervals were reported. RESULTS: Forty-one coho..View full abstract
Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
This work was funded in part by an Australian Research Training Scholarship from the University of Melbourne (M.C.C.), the Gandel Philanthropy Grant (M.C.C.), the David Bickart Clinician Research Award from the University of Melbourne (P.D.C.), the Bushell Postdoctoral Award from the Gastroenterological Society of Australia (P.D.C.), and a National Health & Medical Research Council Early Career Fellowship (P.D.C.).